Service Communautaire d'Information sur la Recherche et le Développement - CORDIS

ERC

OPTIMISE Résumé de rapport

Project ID: 242991
Financé au titre de: FP7-IDEAS-ERC
Pays: United Kingdom

Final Report Summary - OPTIMISE (Optical Platform for Therapy and diagnostic Imaging in Minimally Invasive Surgical Endoscopy)

In the UK, oesophago-gastric cancer is often diagnosed late resulting in only a third of patients being suitable for definitive treatment. The 5-year survival for oesophageal and gastric cancer is 12% and 17% respectively. Despite the need for early detection there remains an inherent risk of missing cancerous lesions during endoscopy. In this research, the combined theranostic potential of gold nanorods in the early diagnosis and treatment gastrointestinal adenocarcinoma was scrutinised. The viability of applying photothermal therapy in human adenocarcinoma ex vivo tissues was assessed, their efficiency and safety was determined in a rodent cancer model and a practical method for simultaneous imaging and therapy of cancer in vivo was designed.

Studies were conducted to establish the optimal gold nanorod concentration and irradiation power required for inducing hyperthermic effects in human and porcine tissues and then evaluate the photothermal effects on ex vivo human oesophageal and gastric adenocarcinoma. Multi-functionalised fluorescent gold nanorods were exposed to human adenocarcinoma cells to test in vitro targeting efficiency using immunohistochemistry and fluorescence microscopy.

A theranostic approach developed from in vivo studies was shown to be effective in identifying tumours and for performing image-guided photothermal therapy. Key principles for successful photothermal therapy were outlined. The theranostic potential offered by functionalised gold nanorods have a place in early and late stage cancers, and can be a valuable adjunct in surgery and endoscopy.

Safety considerations of the application of gold nanorods and photothermal therapy were evaluated in vivo. Gold nanorods were appraised to be inherently safe while harbouring excellent translational potential as effective theranostic tools.

This work has shown that nanotechnology could now be considered for human gastrointestinal tumours. Providing an alternative means of treatment that is effective, cheap and rapid can incur significant improvements in patient prognosis, cancer treatment and quality of life.

Contact

Shaun Power, (Research Services Manager)
Tél.: +44 207 594 8773
Fax: +44 20 7594 8609
E-mail
Numéro d'enregistrement: 183397 / Dernière mise à jour le: 2016-05-26
Source d'information: SESAM